ReviewFrontiers in aging neuroscience2016
Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned.
Review in Frontiers in aging neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease: A Systematic Review.Journal of Parkinson's disease · 2019Pooled it
- Transition dynamics modeling of pre-trained accelerometry representations for time to diagnosis of Parkinson's disease.Lifetime data analysis · 2026Article
- Cholinergic degeneration in prodromal and early Parkinson's disease: a link to present and future disease states.Brain : a journal of neurology · 2026Article
- A New Methodological Approach Integrating Motion Capture and Pressure-Sensitive Gait Data to Assess Functional Mobility in Parkinson's Disease: A Two-Phase Study.Sensors (Basel, Switzerland) · 2025Article
- Multimodal diagnostic tools and advanced data models for detection of prodromal Parkinson's disease: a scoping review.BMC medical imaging · 2025Article
- Predictive potential of circular walking in prodromal Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Article
- Comparison of Transcranial Sonography and [Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Motor Dysfunction in REM Sleep Behavior Disorder: A Rehabilitation Framework for Prodromal Synucleinopathy.Neurorehabilitation and neural repair · 2021Review
- Can detection and prediction models for Alzheimer's Disease be applied to Prodromal Parkinson's Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.Open research Europe · 2021Article
- Missing heritability in Parkinson's disease: the emerging role of non-coding genetic variation.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Future Perspectives on the Relevance of Auditory Markers in Prodromal Parkinson's Disease.Frontiers in neurology · 2020Review
- Hypothyroidism and Cognitive Disorders during Development and Adulthood: Implications in the Central Nervous System.Molecular neurobiology · 2019Review
- The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife.Frontiers in neurology · 2019Review
- Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study.Frontiers in human neuroscience · 2019Article
- From Prodromal to Overt Parkinson's Disease: Towards a New Definition in the Year 2040.Journal of Parkinson's disease · 2018Review
- Article
- Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer's and Parkinson's diseases.GeroScience · 2017Review
- [Diagnostics of clinical and prodromal idiopathic Parkinson's disease : New criteria].Der Nervenarzt · 2017Review
- Improving Dual-Task Walking Paradigms to Detect Prodromal Parkinson's and Alzheimer's Diseases.Frontiers in neurology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing body of evidence supports a prodromal neurodegenerative process preceding the clinical onset of Parkinson's disease (PD). Studies have identified several different prodromal markers that may have the potential to predict the conversion from healthy to clinical PD but use considerably different approaches. We systematically reviewed 35 longitudinal studies reporting prodromal PD features and evaluated the methodological quality across 10 different predefined domains. We found limitations in the following domains: PD diagnosis (57% of studies), prodromal marker assessments (51%), temporal information on prodromal markers or PD diagnosis (34%), generalizability of results (17%), statistical methods (accounting for at least age as confounder; 17%), study design (14%), and sample size (9%). However, no limitations regarding drop-out (or bias investigation), or report of inclusion/exclusion criteria or prodromal marker associations were revealed. Lessons learned from these limitations and additional aspects of current prodromal marker studies in PD are discussed to provide a basis for the evaluation of findings and the improvement of future research in prodromal PD. The observed heterogeneity of studies, limitations and analyses might be addressed in future longitudinal studies using a, yet to be established, modular minimal set of assessments improving comparability of findings and enabling data sharing and combined analyses across studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.